Dengue vaccine acceptance and willingness to pay: a systematic review and meta-analysis

• Published in: Public health (London) 2023-11, Vol.224, p.74-81
• Main Authors: Orellano, P., Reynoso, J., Salomón, O.D., Vezzani, D.
• Format: Article
• Language: English
• Subjects: Dengue; Dengue - prevention & control; Dengue vaccines; Dengue Vaccines - economics; Humans; Meta-analysis; Patient Acceptance of Health Care - psychology; Patient Acceptance of Health Care - statistics & numerical data; Systematic review; Vaccination hesitancy; Vaccination Hesitancy - psychology; Vaccination Hesitancy - statistics & numerical data
• ISSN: 0033-3506; 1476-5616; 1476-5616
• DOI: 10.1016/j.puhe.2023.08.022

Dengue is the most important human vector-borne disease in terms of disease burden. A first dengue vaccine has recently been licenced, and others are in advanced stages of development. However, to date, none of these vaccines has achieved balanced efficacy and safety for all dengue serotypes. The aim of this systematic review and meta-analysis was to assess the global acceptance and willingness to pay for unspecified dengue vaccines. This systematic review and meta-analysis included cross-sectional and cohort studies that reported values for vaccine acceptance (percentage) and willingness to pay for currently available or hypothetical vaccines. These values were pooled using random-effects models for the acceptance, while weighted linear regression was chosen for willingness to pay. Heterogeneity between studies was assessed using prediction intervals (PIs), and a domain-based tool was used to assess the risk of bias. Subgroup and sensitivity analyses were performed where appropriate. This study was registered with PROSPERO (CRD42021255784). We included 19 studies from the Americas and Asia in the quantitative meta-analysis. The risk of bias was mainly related to the selection of participants and to the assumptions about the safety and efficacy of the vaccines. The percentage of vaccine acceptance was 88.3% (95% CI: 81.0%–93.0%), with some heterogeneity between studies (80% PI: 52.9%–98.1%). Willingness to pay was US$ 46.7 (95% CI: 25.9–67.5) per vaccine recipient. There were differences between continents, with higher acceptance in the Americas. We were able to obtain global estimates of vaccine acceptance and willingness to pay and identify the associated factors that influence these values. This knowledge is relevant for the planning of future vaccination strategies.